Soligenix, Inc. (NASDAQ:SNGX) Sees Large Increase in Short Interest

Soligenix, Inc. (NASDAQ:SNGX) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 39,900 shares, a growth of 183.0% from the May 31st total of 14,100 shares. Based on an average daily volume of 198,600 shares, the days-to-cover ratio is currently 0.2 days. Currently, 4.1% of the company’s stock are short sold.

Soligenix Stock Performance

Shares of SNGX traded down $0.07 during mid-day trading on Friday, hitting $2.58. 277,188 shares of the company’s stock were exchanged, compared to its average volume of 145,661. The company has a market cap of $2.55 million, a price-to-earnings ratio of -0.25 and a beta of 1.93. Soligenix has a fifty-two week low of $2.50 and a fifty-two week high of $32.00. The stock’s 50-day moving average is $5.30 and its 200-day moving average is $8.69.

Soligenix (NASDAQ:SNGX) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($2.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.20) by $0.32. The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.20 million. Soligenix had a negative net margin of 1,025.66% and a negative return on equity of 198.36%. As a group, equities research analysts anticipate that Soligenix will post -9.2 EPS for the current year.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.